To assess the association between immune cell density and therapy response, we histopathologically quantified CD45+ immune cells and E-selectin+ inflamed vessel density in surgically resected invasive human breast tumors (Stage II–III), treated with DOX-containing neoadjuvant chemotherapy (Supplementary Figures S1 and S2). Here, PTPRC is linked to breast neoplasm.